Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platformPRNewsWire • 04/28/26
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026PRNewsWire • 04/25/26
Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals OpportunitySeeking Alpha • 04/21/26
Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love24/7 Wall Street • 04/21/26
Is the Options Market Predicting a Spike in Abbott Laboratories Stock?Zacks Investment Research • 04/21/26
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection TestPRNewsWire • 04/17/26
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition dragProactive Investors • 04/16/26